Analysis of Liquidity Ratios
Quarterly Data
Liquidity ratios measure the company ability to meet its short-term obligations.
Liquidity Ratios (Summary)
Johnson & Johnson, liquidity ratios (quarterly data)
Based on: 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
| Liquidity ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Johnson & Johnson current ratio deteriorated from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024. |
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Johnson & Johnson quick ratio deteriorated from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024. |
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Johnson & Johnson cash ratio deteriorated from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024. |
Current Ratio
Johnson & Johnson, current ratio calculation (quarterly data)
| Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | Dec 31, 2021 | Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Current assets | 53,249) | 57,817) | 57,002) | 53,495) | 53,703) | 60,567) | 64,388) | 55,294) | 65,236) | 63,847) | 60,424) | 60,979) | 59,889) | 53,769) | 52,533) | 51,237) | 57,578) | 45,892) | 44,226) | 45,274) | 44,333) | 41,799) | 41,987) | |||||||
| Current liabilities | 51,759) | 53,933) | 48,725) | 46,282) | 44,370) | 54,170) | 60,373) | 55,802) | 45,543) | 44,821) | 43,390) | 45,226) | 44,561) | 38,721) | 40,932) | 42,493) | 38,847) | 36,772) | 33,689) | 35,964) | 35,162) | 31,353) | 29,111) | |||||||
| Liquidity Ratio | ||||||||||||||||||||||||||||||
| Current ratio1 | 1.03 | 1.07 | 1.17 | 1.16 | 1.21 | 1.12 | 1.07 | 0.99 | 1.43 | 1.42 | 1.39 | 1.35 | 1.34 | 1.39 | 1.28 | 1.21 | 1.48 | 1.25 | 1.31 | 1.26 | 1.26 | 1.33 | 1.44 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Current Ratio, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 0.65 | 0.81 | 0.94 | 0.87 | 0.96 | 0.89 | 0.96 | 0.96 | 0.93 | 0.84 | 0.82 | 0.79 | 1.01 | 0.91 | 0.83 | 0.84 | 0.95 | 0.86 | 3.14 | 3.18 | 1.15 | 0.89 | 1.04 | |||||||
| Amgen Inc. | 1.32 | 1.26 | 1.42 | 1.65 | 2.86 | 2.77 | 3.14 | 1.41 | 1.68 | 1.53 | 1.44 | 1.59 | 1.64 | 1.31 | 1.66 | 1.81 | 2.28 | 2.18 | 1.59 | 1.44 | 2.89 | 2.89 | 2.77 | |||||||
| Bristol-Myers Squibb Co. | 1.24 | 1.16 | 1.11 | 1.43 | 1.18 | 1.39 | 1.42 | 1.25 | 1.42 | 1.44 | 1.32 | 1.52 | 1.47 | 1.54 | 1.56 | 1.58 | 1.67 | 1.47 | 1.66 | 1.60 | 3.83 | 3.88 | 1.93 | |||||||
| Danaher Corp. | 1.37 | 1.43 | 1.85 | 1.68 | 2.26 | 2.08 | 1.89 | 1.89 | 1.78 | 1.75 | 1.68 | 1.43 | 1.48 | 2.26 | 2.05 | 1.86 | 2.08 | 2.20 | 1.32 | 5.19 | 3.43 | 2.32 | 2.18 | |||||||
| Eli Lilly & Co. | 1.27 | 1.11 | 1.35 | 0.94 | 1.05 | 1.13 | 1.30 | 1.05 | 1.13 | 1.10 | 1.27 | 1.23 | 1.30 | 1.15 | 1.42 | 1.40 | 1.36 | 1.22 | 1.11 | 1.16 | 1.17 | 1.13 | 1.12 | |||||||
| Gilead Sciences Inc. | 1.26 | 1.14 | 1.08 | 1.43 | 1.34 | 1.02 | 1.28 | 1.29 | 1.30 | 1.43 | 1.48 | 1.27 | 1.37 | 1.36 | 1.37 | 1.40 | 3.25 | 2.33 | 3.04 | 3.10 | 2.96 | 3.76 | 3.62 | |||||||
| Merck & Co. Inc. | 1.36 | 1.47 | 1.25 | 1.25 | 1.38 | 1.28 | 1.44 | 1.47 | 1.46 | 1.39 | 1.40 | 1.27 | 1.31 | 1.31 | 1.02 | 1.02 | 1.30 | 1.32 | 1.11 | 1.24 | 1.26 | 1.21 | 1.37 | |||||||
| Moderna Inc. | 4.39 | 4.09 | 4.03 | 3.42 | 2.46 | 3.39 | 3.46 | 2.73 | 2.10 | 1.99 | 1.77 | 1.76 | 1.35 | 1.24 | 1.39 | 1.43 | 2.43 | 17.30 | 9.29 | 7.89 | 7.40 | 6.77 | 7.17 | |||||||
| Pfizer Inc. | 1.00 | 0.86 | 1.05 | 0.91 | 2.38 | 2.12 | 1.37 | 1.22 | 1.59 | 1.42 | 1.39 | 1.40 | 1.39 | 1.37 | 1.48 | 1.35 | 1.40 | 1.42 | 1.03 | 0.88 | 0.90 | 1.47 | 1.54 | |||||||
| Regeneron Pharmaceuticals Inc. | 5.28 | 5.44 | 5.27 | 5.69 | 5.18 | 5.45 | 5.45 | 5.06 | 5.36 | 5.12 | 4.76 | 3.56 | 3.71 | 3.57 | 3.12 | 3.63 | 3.89 | 2.12 | 4.21 | 3.67 | 4.03 | 3.88 | 4.58 | |||||||
| Thermo Fisher Scientific Inc. | 1.63 | 1.72 | 1.70 | 1.75 | 1.63 | 1.42 | 1.27 | 1.48 | 1.74 | 1.65 | 1.56 | 1.50 | 3.19 | 2.78 | 2.53 | 2.13 | 2.93 | 2.62 | 2.32 | 1.92 | 1.80 | 1.49 | 1.69 | |||||||
Based on: 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2024 Calculation
Current ratio = Current assets ÷ Current liabilities
= 53,249 ÷ 51,759 = 1.03
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Johnson & Johnson current ratio deteriorated from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024. |
Quick Ratio
Johnson & Johnson, quick ratio calculation (quarterly data)
| Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | Dec 31, 2021 | Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Cash and cash equivalents | 19,980) | 24,878) | 25,473) | 21,859) | 19,728) | 21,183) | 19,170) | 14,127) | 11,355) | 10,983) | 10,463) | 14,487) | 17,604) | 14,332) | 12,671) | 13,985) | 18,965) | 11,174) | 15,530) | 17,305) | 16,249) | 14,376) | 14,734) | |||||||
| Restricted cash | —) | —) | —) | —) | —) | —) | 7,695) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Marketable securities | 317) | 597) | 745) | 1,068) | 3,783) | 7,322) | 5,443) | 9,392) | 22,724) | 21,585) | 19,925) | 17,121) | 13,397) | 10,974) | 11,948) | 11,200) | 11,816) | 7,961) | 2,494) | 1,982) | 1,696) | 902) | 602) | |||||||
| Accounts receivable, trade, less allowances | 16,174) | 15,794) | 14,946) | 14,873) | 14,798) | 16,777) | 16,350) | 16,160) | 15,890) | 16,139) | 15,594) | 15,283) | 14,911) | 14,871) | 14,938) | 13,576) | 14,579) | 14,645) | 14,874) | 14,481) | 14,801) | 14,653) | 14,115) | |||||||
| Total quick assets | 36,471) | 41,269) | 41,164) | 37,800) | 38,309) | 45,282) | 48,658) | 39,679) | 49,969) | 48,707) | 45,982) | 46,891) | 45,912) | 40,177) | 39,557) | 38,761) | 45,360) | 33,780) | 32,898) | 33,768) | 32,746) | 29,931) | 29,451) | |||||||
| Current liabilities | 51,759) | 53,933) | 48,725) | 46,282) | 44,370) | 54,170) | 60,373) | 55,802) | 45,543) | 44,821) | 43,390) | 45,226) | 44,561) | 38,721) | 40,932) | 42,493) | 38,847) | 36,772) | 33,689) | 35,964) | 35,162) | 31,353) | 29,111) | |||||||
| Liquidity Ratio | ||||||||||||||||||||||||||||||
| Quick ratio1 | 0.70 | 0.77 | 0.84 | 0.82 | 0.86 | 0.84 | 0.81 | 0.71 | 1.10 | 1.09 | 1.06 | 1.04 | 1.03 | 1.04 | 0.97 | 0.91 | 1.17 | 0.92 | 0.98 | 0.94 | 0.93 | 0.95 | 1.01 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Quick Ratio, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 0.44 | 0.59 | 0.72 | 0.63 | 0.71 | 0.63 | 0.66 | 0.69 | 0.69 | 0.61 | 0.56 | 0.56 | 0.75 | 0.65 | 0.61 | 0.60 | 0.68 | 0.58 | 2.88 | 2.91 | 0.92 | 0.64 | 0.78 | |||||||
| Amgen Inc. | 0.80 | 0.75 | 0.84 | 0.99 | 2.41 | 2.34 | 2.62 | 0.95 | 1.17 | 0.99 | 0.90 | 1.06 | 1.19 | 0.86 | 1.16 | 1.30 | 1.65 | 1.60 | 1.10 | 1.01 | 2.28 | 2.41 | 2.37 | |||||||
| Bristol-Myers Squibb Co. | 0.84 | 0.78 | 0.78 | 1.04 | 0.77 | 0.94 | 1.01 | 0.87 | 0.98 | 1.07 | 1.03 | 1.20 | 1.16 | 1.16 | 1.25 | 1.28 | 1.43 | 1.26 | 1.38 | 1.26 | 3.63 | 3.61 | 1.64 | |||||||
| Danaher Corp. | 0.84 | 0.85 | 1.34 | 1.18 | 1.76 | 1.52 | 1.34 | 1.30 | 1.19 | 1.13 | 1.08 | 0.89 | 0.93 | 1.67 | 1.51 | 1.36 | 1.52 | 1.59 | 0.92 | 4.68 | 2.99 | 1.78 | 1.58 | |||||||
| Eli Lilly & Co. | 0.63 | 0.61 | 0.68 | 0.52 | 0.58 | 0.63 | 0.79 | 0.63 | 0.71 | 0.67 | 0.77 | 0.80 | 0.79 | 0.67 | 0.83 | 0.85 | 0.79 | 0.68 | 0.64 | 0.68 | 0.66 | 0.67 | 0.65 | |||||||
| Gilead Sciences Inc. | 0.82 | 0.69 | 0.72 | 1.06 | 0.98 | 0.78 | 0.95 | 0.99 | 0.96 | 1.06 | 1.06 | 0.95 | 1.01 | 1.05 | 0.99 | 1.08 | 2.93 | 2.09 | 2.78 | 2.86 | 2.74 | 3.41 | 3.32 | |||||||
| Merck & Co. Inc. | 0.88 | 0.88 | 0.68 | 0.68 | 0.83 | 0.74 | 0.90 | 0.93 | 0.90 | 0.85 | 0.84 | 0.73 | 0.78 | 0.75 | 0.58 | 0.58 | 0.77 | 0.84 | 0.66 | 0.78 | 0.80 | 0.75 | 0.88 | |||||||
| Moderna Inc. | 3.83 | 3.66 | 3.64 | 3.15 | 2.15 | 2.78 | 2.87 | 2.29 | 1.62 | 1.55 | 1.44 | 1.52 | 1.21 | 1.13 | 1.30 | 1.37 | 2.35 | 17.01 | 9.10 | 7.74 | 7.22 | 6.64 | 7.01 | |||||||
| Pfizer Inc. | 0.56 | 0.42 | 0.57 | 0.50 | 1.78 | 1.59 | 0.88 | 0.80 | 1.18 | 1.02 | 0.95 | 1.00 | 0.99 | 0.91 | 0.88 | 0.78 | 0.93 | 0.98 | 0.60 | 0.50 | 0.50 | 0.71 | 0.72 | |||||||
| Regeneron Pharmaceuticals Inc. | 4.34 | 4.43 | 4.40 | 4.82 | 4.31 | 4.53 | 4.54 | 4.16 | 4.37 | 4.20 | 3.95 | 2.98 | 3.03 | 2.92 | 2.39 | 2.86 | 3.02 | 1.61 | 3.38 | 2.81 | 3.14 | 2.99 | 3.66 | |||||||
| Thermo Fisher Scientific Inc. | 1.13 | 1.24 | 1.19 | 1.27 | 1.13 | 0.89 | 0.80 | 1.06 | 1.06 | 0.98 | 0.97 | 1.00 | 2.37 | 1.92 | 1.70 | 1.63 | 2.16 | 1.83 | 1.48 | 1.19 | 0.97 | 0.85 | 0.89 | |||||||
Based on: 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2024 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 36,471 ÷ 51,759 = 0.70
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Johnson & Johnson quick ratio deteriorated from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024. |
Cash Ratio
Johnson & Johnson, cash ratio calculation (quarterly data)
| Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Oct 1, 2023 | Jul 2, 2023 | Apr 2, 2023 | Dec 31, 2022 | Oct 2, 2022 | Jul 3, 2022 | Apr 3, 2022 | Dec 31, 2021 | Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Cash and cash equivalents | 19,980) | 24,878) | 25,473) | 21,859) | 19,728) | 21,183) | 19,170) | 14,127) | 11,355) | 10,983) | 10,463) | 14,487) | 17,604) | 14,332) | 12,671) | 13,985) | 18,965) | 11,174) | 15,530) | 17,305) | 16,249) | 14,376) | 14,734) | |||||||
| Restricted cash | —) | —) | —) | —) | —) | —) | 7,695) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Marketable securities | 317) | 597) | 745) | 1,068) | 3,783) | 7,322) | 5,443) | 9,392) | 22,724) | 21,585) | 19,925) | 17,121) | 13,397) | 10,974) | 11,948) | 11,200) | 11,816) | 7,961) | 2,494) | 1,982) | 1,696) | 902) | 602) | |||||||
| Total cash assets | 20,297) | 25,475) | 26,218) | 22,927) | 23,511) | 28,505) | 32,308) | 23,519) | 34,079) | 32,568) | 30,388) | 31,608) | 31,001) | 25,306) | 24,619) | 25,185) | 30,781) | 19,135) | 18,024) | 19,287) | 17,945) | 15,278) | 15,336) | |||||||
| Current liabilities | 51,759) | 53,933) | 48,725) | 46,282) | 44,370) | 54,170) | 60,373) | 55,802) | 45,543) | 44,821) | 43,390) | 45,226) | 44,561) | 38,721) | 40,932) | 42,493) | 38,847) | 36,772) | 33,689) | 35,964) | 35,162) | 31,353) | 29,111) | |||||||
| Liquidity Ratio | ||||||||||||||||||||||||||||||
| Cash ratio1 | 0.39 | 0.47 | 0.54 | 0.50 | 0.53 | 0.53 | 0.54 | 0.42 | 0.75 | 0.73 | 0.70 | 0.70 | 0.70 | 0.65 | 0.60 | 0.59 | 0.79 | 0.52 | 0.54 | 0.54 | 0.51 | 0.49 | 0.53 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Cash Ratio, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 0.17 | 0.31 | 0.44 | 0.34 | 0.38 | 0.27 | 0.24 | 0.31 | 0.36 | 0.29 | 0.23 | 0.28 | 0.43 | 0.30 | 0.31 | 0.30 | 0.33 | 0.25 | 2.50 | 2.56 | 0.61 | 0.32 | 0.38 | |||||||
| Amgen Inc. | 0.44 | 0.43 | 0.49 | 0.60 | 2.05 | 2.00 | 2.22 | 0.59 | 0.80 | 0.57 | 0.51 | 0.66 | 0.87 | 0.55 | 0.82 | 0.91 | 1.24 | 1.09 | 0.68 | 0.69 | 1.94 | 2.05 | 2.07 | |||||||
| Bristol-Myers Squibb Co. | 0.36 | 0.29 | 0.37 | 0.55 | 0.33 | 0.43 | 0.49 | 0.42 | 0.48 | 0.63 | 0.66 | 0.78 | 0.73 | 0.68 | 0.75 | 0.83 | 1.03 | 0.92 | 0.95 | 0.84 | 3.10 | 3.02 | 0.99 | |||||||
| Danaher Corp. | 0.36 | 0.35 | 0.90 | 0.71 | 1.31 | 1.02 | 0.85 | 0.71 | 0.64 | 0.53 | 0.49 | 0.32 | 0.35 | 1.07 | 0.93 | 0.82 | 0.94 | 0.99 | 0.52 | 4.04 | 2.40 | 1.08 | 0.84 | |||||||
| Eli Lilly & Co. | 0.14 | 0.12 | 0.14 | 0.11 | 0.11 | 0.15 | 0.23 | 0.13 | 0.18 | 0.18 | 0.19 | 0.26 | 0.28 | 0.22 | 0.26 | 0.29 | 0.30 | 0.20 | 0.14 | 0.21 | 0.15 | 0.20 | 0.19 | |||||||
| Gilead Sciences Inc. | 0.43 | 0.26 | 0.36 | 0.64 | 0.57 | 0.48 | 0.56 | 0.57 | 0.54 | 0.61 | 0.62 | 0.56 | 0.56 | 0.64 | 0.58 | 0.65 | 2.52 | 1.79 | 2.34 | 2.50 | 2.39 | 3.03 | 2.97 | |||||||
| Merck & Co. Inc. | 0.49 | 0.44 | 0.22 | 0.28 | 0.38 | 0.27 | 0.45 | 0.54 | 0.49 | 0.44 | 0.40 | 0.34 | 0.42 | 0.39 | 0.26 | 0.30 | 0.36 | 0.50 | 0.32 | 0.47 | 0.39 | 0.35 | 0.47 | |||||||
| Moderna Inc. | 3.12 | 3.59 | 3.58 | 2.85 | 1.73 | 2.71 | 2.55 | 2.01 | 1.23 | 1.16 | 1.09 | 1.18 | 0.89 | 0.90 | 0.92 | 1.05 | 2.22 | 16.81 | 9.05 | 7.71 | 7.16 | 6.61 | 6.97 | |||||||
| Pfizer Inc. | 0.23 | 0.16 | 0.29 | 0.27 | 1.42 | 1.29 | 0.55 | 0.54 | 0.82 | 0.70 | 0.61 | 0.73 | 0.71 | 0.61 | 0.51 | 0.47 | 0.64 | 0.70 | 0.31 | 0.26 | 0.25 | 0.40 | 0.39 | |||||||
| Regeneron Pharmaceuticals Inc. | 2.68 | 2.80 | 2.94 | 3.17 | 2.75 | 2.88 | 2.89 | 2.46 | 2.44 | 2.49 | 2.34 | 1.45 | 1.56 | 1.05 | 1.09 | 1.33 | 1.29 | 0.85 | 1.95 | 1.53 | 1.63 | 1.56 | 2.14 | |||||||
| Thermo Fisher Scientific Inc. | 0.46 | 0.60 | 0.52 | 0.58 | 0.43 | 0.22 | 0.22 | 0.50 | 0.26 | 0.17 | 0.23 | 0.33 | 1.55 | 1.01 | 0.80 | 1.00 | 1.21 | 0.97 | 0.54 | 0.39 | 0.22 | 0.30 | 0.19 | |||||||
Based on: 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2024 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 20,297 ÷ 51,759 = 0.39
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Johnson & Johnson cash ratio deteriorated from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024. |